Plan Early: Optimizing Stability During Lyophilization

Pharmaceutical Technology, Pharmaceutical Technology, Trends in Manufacturing, May 2022, Volume 2022 eBook, Issue 2
Pages: 22-29

The need for sustainability and early considerations of a lyophilization strategy grow more pertinent on the back of growing biologics volume.

Lyophilization remains an integral step in the manufacturing process for certain biotherapeutics, as was demonstrated with the COVID-19 vaccines. Lyophilization is also important in traditional biologic manufacturing and for emerging therapies. However, there remains inherent risk in subjecting these biomolecules through successive freeze-thaw cycles, which call for best-practice procedures to ensure that product viability and stability are maintained during the lyophilization process. Furthermore, questions have arisen about the long-term sustainability of current lyophilization techniques as the development of new biologic and emerging therapy drug candidates continues to grow.

Read this article in the Trends in Manufacturing ebook.

Reference

1. EC, “EU Legislation to Control F-gases,” ec.europa.eu, accessedJan. 14, 2022.

About the author

Feliza Mirasol is the science editor for Pharmaceutical Technology and Pharmaceutical Technology Europe.

Article details

Pharmaceutical Technology
eBook: Trends in Manufacturing
May 2022
Pages: 22-29

Citation

When referring to this article, please cite it as F. Mirasol, “Plan Early: Optimizing Stability During Lyophilization,” Pharmaceutical Technology Trends in Manufacturing eBook (May 2022).